Skip to main content

Communicable Diseases

0
Pipeline Programs
4
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Enterprise Therapeutics
1 program
Online disease surveillance data accessN/A1 trial
Active Trials
NCT01232686Completed200Est. Dec 2012
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
PlasmaN/A2 trials
Active Trials
NCT02338986Completed10Est. May 2025
NCT00029445Recruiting400
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
SAFE Employment TrainingN/A1 trial
Active Trials
NCT06112249Completed67Est. Sep 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
TailoredN/A1 trial
Active Trials
NCT02665013Completed824Est. May 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Temple TherapeuticsSAFE Employment Training
Colorado TherapeuticsTailored
Allergy TherapeuticsPlasma
Enterprise TherapeuticsOnline disease surveillance data access
Allergy TherapeuticsPlasma

Clinical Trials (5)

Total enrollment: 1,501 patients across 5 trials

NCT06112249Temple TherapeuticsSAFE Employment Training

SAFE Workplace Intervention for People With IDD

Start: Oct 2023Est. completion: Sep 202567 patients
N/ACompleted
NCT02665013Colorado TherapeuticsTailored

Reducing Delay of Vaccination in Children Study

Start: Apr 2016Est. completion: May 2019824 patients
N/ACompleted
NCT02338986Allergy TherapeuticsPlasma

Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases

Start: Mar 2015Est. completion: May 202510 patients
N/ACompleted
NCT01232686Enterprise TherapeuticsOnline disease surveillance data access

Snow Disease Surveillance System Study

Start: Oct 2010Est. completion: Dec 2012200 patients
N/ACompleted
NCT00029445Allergy TherapeuticsPlasma

Leukapheresis to Obtain Plasma or Lymphocytes for Studies of HIV-infected Patients, Including Long-term Non-progressors

Start: Aug 2001400 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,501 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.